EUVIMEDEUVIMED entdecken
Crossref

Study finds GLP‐1 RAs reduced 4‐year mortality by 24% compared to SGLT2 inhibitors in people with SMI

The Brown University Psychopharmacology Update · 2026-12 · 37 (12) · 1-5

DOI: 10.1002/pu.31517 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Brown University Psychopharmacology Update, online erschienen am 14.11.2026.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The mortality gap for people with bipolar disorder, major depressive disorder, and schizophrenia is mainly due to cardiovascular disease. Individuals with serious mental illness (SMI) have a life expectancy of 10 to 25 years shorter than the general population. This is partly due to psychopharmacotherapy‐related metabolic effects and systemic disparities in prevention and treatment, leading to the need to find interventions that address cardiovascular outcomes and metabolic risk.

Zitieren

APA

(2026). Study finds GLP‐1 RAs reduced 4‐year mortality by 24% compared to SGLT2 inhibitors in people with SMI. The Brown University Psychopharmacology Update, 37(12), 1-5. https://doi.org/10.1002/pu.31517

Vancouver

Study finds GLP‐1 RAs reduced 4‐year mortality by 24% compared to SGLT2 inhibitors in people with SMI. The Brown University Psychopharmacology Update. 2026;37(12):1-5. doi:10.1002/pu.31517

BibTeX
@article{euvimed2026,
  title = {Study finds GLP‐1 RAs reduced 4‐year mortality by 24% compared to SGLT2 inhibitors in people with SMI},
  journal = {The Brown University Psychopharmacology Update},
  year = {2026},
  volume = {37},
  number = {12},
  pages = {1--5},
  doi = {10.1002/pu.31517}
}
Kostenlos starten →